Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Nivolumab Plus Ipilimumab Demonstrates Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial - The Lancet Oncology

ASCO GU 2023: EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA-617 Therapy Versus 177Lu-PSMA-617 in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC; ANZUP 2001)

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study

ICU :: Investigative and Clinical Urology

Cancers, Free Full-Text

Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?

Cancers, Free Full-Text

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial - ScienceDirect

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Frontiers Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy